{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alprazolam+2+mg",
    "query": {
      "intervention": "Alprazolam 2 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 31,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alprazolam+2+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T12:55:58.026Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01188031",
      "title": "A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG",
          "type": "DRUG"
        },
        {
          "name": "NIRAVAM TM 2 mg orally disintegrating tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-06",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2010-08-25",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188031"
    },
    {
      "nct_id": "NCT00356278",
      "title": "D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stress Disorder, Post Traumatic"
      ],
      "interventions": [
        {
          "name": "D-Cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Virtual Reality Exposure Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 156,
      "start_date": "2006-09",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-01-08",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00356278"
    },
    {
      "nct_id": "NCT06097676",
      "title": "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Abuse Potential"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbor Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 86,
      "start_date": "2021-09-28",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097676"
    },
    {
      "nct_id": "NCT03220113",
      "title": "Treatment of Chronic Migraine Headaches.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Migraine Without Aura, Intractable",
        "Migraine With Typical Aura",
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "Dexamethasone, Lidocaine, Thiamine cohort",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Corona Doctors Medical Clinics, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "10 Years to 90 Years"
      },
      "enrollment_count": 100,
      "start_date": "2017-07-01",
      "completion_date": "2019-07-01",
      "has_results": false,
      "last_update_posted_date": "2018-04-04",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "Corona, California",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220113"
    },
    {
      "nct_id": "NCT00603980",
      "title": "Staccato Alprazolam Abuse Liability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Abuse Liability of Staccato Alprazolam"
      ],
      "interventions": [
        {
          "name": "Inhaled placebo + oral placebo",
          "type": "DRUG"
        },
        {
          "name": "Inhaled alprazolam 0.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Inhaled alprazolam 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Inhaled alprazolam 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Oral alprazolam 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Oral alprazolam 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Oral alprazolam 4 m",
          "type": "DRUG"
        },
        {
          "name": "Oral alprazolam 2 mg qualifying session",
          "type": "DRUG"
        },
        {
          "name": "Oral placebo qualifying session",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nova Pneuma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 31,
      "start_date": "2008-01",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00603980"
    },
    {
      "nct_id": "NCT01188057",
      "title": "A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG",
          "type": "DRUG"
        },
        {
          "name": "NIRAVAM TM 2 mg orally disintegrating tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-07",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2010-08-25",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188057"
    },
    {
      "nct_id": "NCT00703885",
      "title": "PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety Disorders"
      ],
      "interventions": [
        {
          "name": "0.25 mg alprazolam",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg alprazolam",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-01",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2014-12-22",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00703885"
    },
    {
      "nct_id": "NCT02351115",
      "title": "Staccato Alprazolam and Photoparoxysmal Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "A=Placebo",
          "type": "DRUG"
        },
        {
          "name": "B=Inhaled Alprazolam 0.5 mg",
          "type": "DRUG"
        },
        {
          "name": "C=Inhaled Alprazolam 1 m",
          "type": "DRUG"
        },
        {
          "name": "D= Inhaled Alprazolam 2 mg",
          "type": "DRUG"
        },
        {
          "name": "E=Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nova Pneuma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 5,
      "start_date": "2015-01",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 3,
      "location_summary": "Boise, Idaho • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02351115"
    },
    {
      "nct_id": "NCT00865761",
      "title": "A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Alprazolam 3 mg Extended Release Tablets, single dose",
          "type": "DRUG"
        },
        {
          "name": "XANAX XR® 3 mg tablets, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2005-09",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2010-08-17",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865761"
    },
    {
      "nct_id": "NCT00634790",
      "title": "A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Panic Disorder"
      ],
      "interventions": [
        {
          "name": "alprazolam XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 49,
      "start_date": "2004-05",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-09-12T12:55:58.026Z",
      "location_count": 47,
      "location_summary": "Little Rock, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 43 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "El Centro",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634790"
    }
  ]
}